PharmAla Biotech Signs $100 Million-Plus Term Sheet to License ALA-002 MDMA Therapeutic to Jupiter Neurosciences
PharmAla Biotech has signed a term sheet granting Jupiter Neurosciences, Inc. (NASDAQ: JUNS) exclusive U.S. licensing rights to ALA-002, its next-generation MDMA therapeutic, in a transaction valued at over $100…
Filed via globenewswire.com